Good day, and compliments of the season.
I am preparing an Expression of Interest for the Far-UVC for Infection Reduction (FIR) program through Blueprint Biosecurity. I plan to use a nasal swab–based protocol as the primary endpoint.

If you have experience with clinical trials, respiratory infection endpoints, or study design in real-world settings, I would greatly value your feedback on the EOI. Please feel free to reach out (eennadi@gmail.com) or comment here.

RFP: https://blueprintbiosecurity.org/calls-for-proposals/request-for-proposals-far-uvc-for-infection-reduction-fir-protocol/

Thank you in advance for any insights or pointers.